ESSA PHARMA INC. REPORTS RESULTS OF ANNUAL GENERAL MEETING OF SHAREHOLDERS
ESSA Pharma Inc. (NASDAQ: EPIX) held its Annual General Meeting of Shareholders on March 5, 2025.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
ESSA Pharma Inc. (NASDAQ: EPIX) held its Annual General Meeting of Shareholders on March 5, 2025. The company, which previously focused on developing prostate cancer therapies before discontinuing its clinical trials and development programs, announced key shareholder votes.
Shareholders approved setting the board size at seven directors and re-elected David R. Parkinson, Richard M. Glickman, Franklin M. Berger, Scott Requadt, Marella Thorell, Alex Martin, and Sandy Zweifach. Additional approvals included the re-appointment of Davidson & Company LLP as auditors and a non-binding advisory vote on executive compensation.
Positive
- All proposed board members successfully re-elected
- Shareholder approval received for all agenda items
Negative
- Clinical trials and development programs discontinued
- No active drug development pipeline
Details
News Market Reaction – EPIX
The recorded move for EPIX in the trading session of this news was -1.78%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOUTH SAN FRANCISCO,
At the Meeting, the shareholders of the Company (the "Shareholders") resolved to set the number of directors of the Company at seven and re-elected to the board of directors, by ordinary resolution passed by ballot vote, David R. Parkinson, Richard M. Glickman, Franklin M. Berger, Scott Requadt, Marella Thorell, Alex Martin and Sandy Zweifach to serve in office until the next annual meeting or until their successors are duly elected or appointed. Detailed results of the voting in respect of the election of directors are as follows:
Nominee | Votes For | % Votes For | Votes Withheld | % Votes Withheld |
David R. Parkinson | 9,131,148 | 98.83 % | 108,123 | 1.17 % |
Richard M. Glickman | 8,823,885 | 95.50 % | 415,386 | 4.50 % |
Franklin M. Berger | 8,807,588 | 95.33 % | 431,683 | 4.67 % |
Scott Requadt | 9,130,637 | 98.82 % | 108,634 | 1.18 % |
Marella Thorell | 9,135,934 | 98.88 % | 103,337 | 1.12 % |
Alex Martin | 9,132,226 | 98.84 % | 107,045 | 1.16 % |
Sandy Zweifach | 9,112,900 | 98.63 % | 126,371 | 1.37 % |
At the Meeting, the Shareholders also approved: (i) the re-appointment of Davidson & Company LLP, Chartered Professional Accountants, as auditors of the Company; and (ii) on a non-binding advisory basis, the compensation of the Company's named executive officers.
Contact Information:
David Wood
Chief Financial Officer, ESSA Pharma Inc.
T: 778-331-0962
E: dwood@essapharma.com
About ESSA Pharma Inc.
ESSA is a pharmaceutical company that was previously focused on developing novel and proprietary therapies for the treatment of patients with prostate cancer. For more information, please visit www.essapharma.com.
View original content:https://www.prnewswire.com/news-releases/essa-pharma-inc-reports-results-of-annual-general-meeting-of-shareholders-302394301.html
SOURCE ESSA Pharma Inc
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.